Diagnosis Summary

• ~29% risk of progression to endometrial carcinoma if untreated
• Up to 40-50% of women with atypical hyperplasia may have a concurrent undiagnosed carcinoma found at hysterectomy
• No definitive invasive carcinoma is seen on this biopsy, but correlation with radiology is advised

Treatment - Based on Fertility Desire

Management Flowchart

Option A: Does NOT Desire Fertility (Standard / Definitive Treatment)

• Rules out concurrent carcinoma (present in 25-43% of atypical hyperplasia cases)
• Bilateral salpingo-oophorectomy (BSO) may also be considered
• No further hormonal treatment needed post-operatively if benign at final pathology

"For women with atypical complex hyperplasia who no longer desire fertility, hysterectomy is recommended." - Berek & Novak's Gynecology

Option B: Desires Fertility Preservation (Conservative / Hormonal Treatment)

• Levonorgestrel-IUD is an effective alternative with fewer systemic side effects
• Overall response rate to progestin therapy: ~76%
• Median time to regression: 12 weeks

• If normal/atrophic endometrium: Continue Provera 5 mg/day x 10 days/month for 12 months + annual biopsy. Consider ovulation induction if pregnancy desired.
• If persistent atypical hyperplasia: Escalate to high-dose progestins (Provera 40-100 mg/day for 3 months)
• If still persistent after high-dose: Proceed to hysterectomy

Special Notes

1. This biopsy specifically states "invasive carcinoma not seen" - but this does NOT exclude carcinoma. Up to 43% of atypical hyperplasia patients are found to have carcinoma at hysterectomy.
2. MRI of the pelvis should be done to evaluate myometrial invasion depth before any fertility-sparing decision.
3. Recurrence after progestin treatment is ~24-50% - most within 1 year. Surveillance is mandatory.
4. Progestin therapy is a temporary bridge, not a definitive cure in atypical hyperplasia - hysterectomy remains the gold standard once fertility is no longer desired.
5. The report advises radiologic correlation - this must be done (MRI pelvis) before finalizing management.

Medical Abortion (Mifepristone + Misoprostol) in Seizure Disorder - Can it be Given?

Short Answer: Yes, with important precautions - seizure disorder is NOT a contraindication, but drug interactions with antiepileptic drugs (AEDs) must be managed carefully.

Established Contraindications to Medical Abortion

• Confirmed/suspected ectopic pregnancy
• IUD in place (must be removed first)
• Chronic adrenal failure
• Long-term corticosteroid therapy
• Allergy to mifepristone, misoprostol, or other prostaglandins
• Hemorrhagic disorder / coagulopathy
• Inherited porphyria

• Berek & Novak's Gynecology, p. 781
• Ipas Clinical Guidelines

The Key Issue: Drug Interaction with Enzyme-Inducing AEDs

"The dose of mifepristone may be increased in patients who take antiepileptic drugs that augment the hepatic P450 system that metabolizes mifepristone (i.e., phenytoin, phenobarbital, carbamazepine, and oxcarbazepine)." - Society of Family Planning Guidelines

Management Recommendations

1. Dose Adjustment

• If the patient is on enzyme-inducing AEDs (phenytoin, phenobarbital, carbamazepine, oxcarbazepine), consider increasing mifepristone dose up to 600 mg (maximum approved safe dose, compared to the standard 200 mg)
• No specific research data define the exact adjusted dose - clinical judgment applies

2. Route of Misoprostol

• Vaginal or buccal misoprostol is preferred over oral in patients with risk factors, as absorption is more reliable
• Misoprostol itself does not lower the seizure threshold in standard doses; no direct seizure risk has been established

3. AED Levels

• The stress of the abortion procedure and associated nausea/vomiting (which can impair AED absorption) may temporarily affect seizure control
• Ensure the patient maintains AED dosing before and after the procedure
• Vaginal/buccal misoprostol avoids GI absorption issues that could impair AED levels

4. Setting

• For women on multiple AEDs or with poorly controlled epilepsy, abortion should be performed in a hospital or supervised clinical setting rather than at home
• Have seizure rescue medications (e.g., benzodiazepines) accessible

5. If Mifepristone is Still a Concern

• A misoprostol-only regimen (800 mcg vaginally, repeated in 24 hours if needed) is an effective alternative, with ~91% complete abortion rate up to 56 days of amenorrhea
• Surgical vacuum aspiration remains the safest option when there is genuine uncertainty about medical management

Summary Table